The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Supranuclear Palsy, Progressive

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Supranuclear Palsy, Progressive


Psychiatry related information on Supranuclear Palsy, Progressive


High impact information on Supranuclear Palsy, Progressive


Chemical compound and disease context of Supranuclear Palsy, Progressive


Biological context of Supranuclear Palsy, Progressive


Anatomical context of Supranuclear Palsy, Progressive


Gene context of Supranuclear Palsy, Progressive


Analytical, diagnostic and therapeutic context of Supranuclear Palsy, Progressive


  1. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Jackson, G.R., Wiedau-Pazos, M., Sang, T.K., Wagle, N., Brown, C.A., Massachi, S., Geschwind, D.H. Neuron (2002) [Pubmed]
  2. Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases. Manetto, V., Perry, G., Tabaton, M., Mulvihill, P., Fried, V.A., Smith, H.T., Gambetti, P., Autilio-Gambetti, L. Proc. Natl. Acad. Sci. U.S.A. (1988) [Pubmed]
  3. FDG PET in the differential diagnosis of parkinsonian disorders. Eckert, T., Barnes, A., Dhawan, V., Frucht, S., Gordon, M.F., Feigin, A.S., Eidelberg, D. Neuroimage (2005) [Pubmed]
  4. Dystonia in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Rivest, J., Quinn, N., Marsden, C.D. Neurology (1990) [Pubmed]
  5. Brain destruction alone does not elevate brain aluminum. Traub, R.D., Rains, T.C., Garruto, R.M., Gajdusek, D.C., Gibbs, C.J. Neurology (1981) [Pubmed]
  6. Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects? Litvan, I., FitzGibbon, E.J. Neurology (1996) [Pubmed]
  7. Differential diagnosis of Alzheimer's disease. Geldmacher, D.S., Whitehouse, P.J. Neurology (1997) [Pubmed]
  8. Increased wave P 300 latency in progressive supranuclear palsy. Pierrot-Deseilligny, C., Turell, E., Penet, C., Lebrigand, D., Pillon, B., Chain, F., Agid, Y. J. Neurol. Neurosurg. Psychiatr. (1989) [Pubmed]
  9. "Apraxia of eyelid opening" induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case report. Defazio, G., De Mari, M., De Salvia, R., Lamberti, P., Giorelli, M., Livrea, P. Clinical neuropharmacology. (1999) [Pubmed]
  10. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X., Duff, K., Hardy, J., Corral, A., Lin, W.L., Yen, S.H., Dickson, D.W., Davies, P., Hutton, M. Nat. Genet. (2000) [Pubmed]
  11. Zolpidem in progressive supranuclear palsy. Daniele, A., Moro, E., Bentivoglio, A.R. N. Engl. J. Med. (1999) [Pubmed]
  12. Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography. Baron, J.C., Maziere, B., Loc'h, C., Sgouropoulos, P., Bonnet, A.M., Agid, Y. Lancet (1985) [Pubmed]
  13. Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease. Ferrer, I., Barrachina, M., Tolnay, M., Rey, M.J., Vidal, N., Carmona, M., Blanco, R., Puig, B. Brain Pathol. (2003) [Pubmed]
  14. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Ferrer, I., Blanco, R., Carmona, M., Ribera, R., Goutan, E., Puig, B., Rey, M.J., Cardozo, A., Viñals, F., Ribalta, T. Brain Pathol. (2001) [Pubmed]
  15. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Jenner, P., Dexter, D.T., Sian, J., Schapira, A.H., Marsden, C.D. Ann. Neurol. (1992) [Pubmed]
  16. PET measures of benzodiazepine receptors in progressive supranuclear palsy. Foster, N.L., Minoshima, S., Johanns, J., Little, R., Heumann, M.L., Kuhl, D.E., Gilman, S. Neurology (2000) [Pubmed]
  17. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Litvan, I., Phipps, M., Pharr, V.L., Hallett, M., Grafman, J., Salazar, A. Neurology (2001) [Pubmed]
  18. Pramipexole in progressive supranuclear palsy. Weiner, W.J., Minagar, A., Shulman, L.M. Neurology (1999) [Pubmed]
  19. Idazoxan treatment in progressive supranuclear palsy. Ghika, J., Tennis, M., Hoffman, E., Schoenfeld, D., Growdon, J. Neurology (1991) [Pubmed]
  20. Apolipoprotein E epsilon 4 allele frequency is not increased in progressive supranuclear palsy. Tabaton, M., Rolleri, M., Masturzo, P., Cammarata, S., Angelini, G., Hansen, L.A., Saitoh, T., Petersen, R.B., Perry, G., Richey, P. Neurology (1995) [Pubmed]
  21. Progressive supranuclear gaze palsy is in linkage disequilibrium with the tau and not the alpha-synuclein gene. Higgins, J.J., Litvan, I., Pho, L.T., Li, W., Nee, L.E. Neurology (1998) [Pubmed]
  22. Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3. Zainelli, G.M., Dudek, N.L., Ross, C.A., Kim, S.Y., Muma, N.A. J. Neuropathol. Exp. Neurol. (2005) [Pubmed]
  23. Association between the extended tau haplotype and frontotemporal dementia. Verpillat, P., Camuzat, A., Hannequin, D., Thomas-Anterion, C., Puel, M., Belliard, S., Dubois, B., Didic, M., Michel, B.F., Lacomblez, L., Moreaud, O., Sellal, F., Golfier, V., Campion, D., Clerget-Darpoux, F., Brice, A. Arch. Neurol. (2002) [Pubmed]
  24. Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Chinaglia, G., Landwehrmeyer, B., Probst, A., Palacios, J.M. Neuroscience (1993) [Pubmed]
  25. The nucleus raphe interpositus in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Revesz, T., Sangha, H., Daniel, S.E. Brain (1996) [Pubmed]
  26. Progressive supranuclear palsy: loss of choline-acetyltransferase-like immunoreactive neurons in the pontine reticular formation. Malessa, S., Hirsch, E.C., Cervera, P., Javoy-Agid, F., Duyckaerts, C., Hauw, J.J., Agid, Y. Neurology (1991) [Pubmed]
  27. Mesencephalic cholinergic nuclei in progressive supranuclear palsy. Juncos, J.L., Hirsch, E.C., Malessa, S., Duyckaerts, C., Hersh, L.B., Agid, Y. Neurology (1991) [Pubmed]
  28. Selective decrease of large neurons in the neostriatum in progressive supranuclear palsy. Oyanagi, K., Takahashi, H., Wakabayashi, K., Ikuta, F. Brain Res. (1988) [Pubmed]
  29. Formic acid treatment exposes hidden neurofilament and tau epitopes in abnormal cytoskeletal filaments from patients with progressive supranuclear palsy and Alzheimer's disease. Cammarata, S., Mancardi, G., Tabaton, M. Neurosci. Lett. (1990) [Pubmed]
  30. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Poorkaj, P., Muma, N.A., Zhukareva, V., Cochran, E.J., Shannon, K.M., Hurtig, H., Koller, W.C., Bird, T.D., Trojanowski, J.Q., Lee, V.M., Schellenberg, G.D. Ann. Neurol. (2002) [Pubmed]
  31. Apolipoprotein E in progressive supranuclear palsy in Japan. Sawa, A., Amano, N., Yamada, N., Kajio, H., Yagishita, S., Takahashi, T., Oda, M., Arai, N., Ikeda, K., Tadokoro, M., Matsushita, M. Mol. Psychiatry (1997) [Pubmed]
  32. Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. Lorenzl, S., Albers, D.S., Chirichigno, J.W., Augood, S.J., Beal, M.F. J. Neurol. Sci. (2004) [Pubmed]
  33. Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy. Borghi, R., Giliberto, L., Assini, A., Delacourte, A., Perry, G., Smith, M.A., Strocchi, P., Zaccheo, D., Tabaton, M. Neurology (2002) [Pubmed]
  34. Multiple system atrophy/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE. Morris, H.R., Vaughan, J.R., Datta, S.R., Bandopadhyay, R., Rohan De Silva, H.A., Schrag, A., Cairns, N.J., Burn, D., Nath, U., Lantos, P.L., Daniel, S., Lees, A.J., Quinn, N.P., Wood, N.W. Neurology (2000) [Pubmed]
  35. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Blin, J., Baron, J.C., Dubois, B., Pillon, B., Cambon, H., Cambier, J., Agid, Y. Arch. Neurol. (1990) [Pubmed]
  36. Sequence analysis of tau 3'untranslated region and saitohin gene in sporadic progressive supranuclear palsy. Ezquerra, M., Campdelacreu, J., Muñoz, E., Oliva, R., Tolosa, E. J. Neurol. Neurosurg. Psychiatr. (2004) [Pubmed]
  37. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. Brücke, T., Asenbaum, S., Pirker, W., Djamshidian, S., Wenger, S., Wöber, C., Müller, C., Podreka, I. J. Neural Transm. Suppl. (1997) [Pubmed]
  38. Bcl-2 and Bax protein expression in neurofibrillary tangles in progressive supranuclear palsy. Tortosa, A., Blanco, R., Ferrer, I. Neuroreport (1998) [Pubmed]
  39. Initial studies with high resolution TEM and electron energy loss spectroscopy studies of ferritin cores extracted from brains of patients with progressive supranuclear palsy and Alzheimer disease. Quintana, C., Lancin, M., Marhic, C., Pérez, M., Martin-Benito, J., Avila, J., Carrascosa, J.L. Cell. Mol. Biol. (Noisy-le-grand) (2000) [Pubmed]
WikiGenes - Universities